Sensitive and selective detection of free FXIII activation peptide: A potential marker of acute thrombotic events

Blood

Volumn 115, Issue 24, 2010, Pages 5089-5096

  Ortner, Elisabeth ^a   Schroeder, Verena ^a   Walser, Reto ^b   Zerbe, Oliver ^b   Kohler, Hans P ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Spital Netz Bern   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13; MONOCLONAL ANTIBODY; MONOMER; FACTOR XIII ACTIVATION PEPTIDE; PEPTIDE; PROTEIN SUBUNIT;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURFACE PLASMON RESONANCE; THROMBOSIS; ACUTE DISEASE; ANIMAL; ANTIBODY SPECIFICITY; BINDING SITE; BLOOD; CHEMISTRY; CIRCULAR DICHROISM; DIMERIZATION; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES; BIOLOGICAL MARKERS; CIRCULAR DICHROISM; DIMERIZATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FACTOR XIII; HUMANS; MICE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PROTEIN SUBUNITS; SURFACE PLASMON RESONANCE; THROMBOSIS;

EID: 77954670211     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-253062     Document Type: Article

References (33)

1. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem. 2008;6(3):190-205.
2. Kohler HP. Role of blood coagulation factor XIII in vascular diseases. Swiss Med Wkly. 2001;131(3-4):31-34. (Pubitemid 32229955)
3. Kohler HP, Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost. 1999;82(3):1202-1203.
4. Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost. 1998;79(1):8-13.
5. Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-dimer, and clot firmness. Thromb Haemost. 2003;90(3):434-438. (Pubitemid 37138768)
6. Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39(8):2280-2287.
7. Schroeder V, Vuissoz JM, Caflisch A, Kohler HP. Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared with its bound form. Thromb Haemost. 2007;97(6):890-898.
8. Yee VC, Pedersen LC, Le Trong I, Bishop PD, Stenkamp RE, Teller DC. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proc Natl Acad Sci U S A. 1994;91(15):7296-7300. (Pubitemid 24226850)
9. Yee VC, Pedersen LC, Bishop PD, Stenkamp RE, Teller DC. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII. Thromb Res. 1995;78(5):389-397.
10. Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 1998;423(3):291-296.
11. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18(15):2714-2723.
12. Nice EC, Catimel B. Instrumental biosensors: new perspectives for the analysis of biomolecular interactions. Bioessays. 1999;21(4):339-352. (Pubitemid 29211960)
13. Kohno T, Kusunoki H, Sato K, Wakamatsu K. A new general method for the biosynthesis of stable isotope-enriched peptides using a decahistidine-tagged ubiquitin fusion system: an application to the production of mastoparan-X uniformly enriched with 15N and 15N/13C. J Biomol NMR. 1998;12(1):109-121.
14. Miroux B, Walker JE. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J Mol Biol. 1996;260(3):289-298.
15. Cavangh J, Fairbrother WJ, Palmer AG, Skelton NJ. Protein NMR Spectroscopy: Principles and Practice. San Diego, CA: Academic Press; 1996.
16. Wüthrich K. NMR of Proteins and Nucleic Acids. 1st ed. New York, NY: John Wiley & Sons; 1986.
17. Noggle JH, Schirmer RE. The Nuclear Overhauser Effect-Chemical Applications. New York, NY: Academic Press; 1971.
18. Bartels C, Billeter M, Güntert P, Wüthrich K. The program XEASY for computer-supported NMR spectral analysis of biological macromolecules. J Biomol NMR. 1995;6(1):1-10.
19. Keller R. The Computer Aided Resonance Assignment. Goldau, Switzerland: Cantina Verlag; 2004.
20. Trumbo TA, Maurer MC. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P(9) and P(4) positions in factor XIII activation. Biochemistry. 2002;41(8):2859-2868.
21. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. 1999;93(3):906-908. (Pubitemid 29067855)
22. Franco RF, Pazin-Filho A, Tavella MH, Simoes MV, Marin-Neto JA, Zago MA. Factor XIII Val34Leu and the risk of myocardial infarction. Haematologica. 2000;85(1):67-71.
23. Franco RF, Reitsma PH, Lourenco D, et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost. 1999;81(5):676-679.
24. Wartiovaara U, Perola M, Mikkola H, et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis. 1999;142(2):295-300.
25. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 2007;97(4):635-641. (Pubitemid 46592942)
26. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164(2):101-109.
27. Vokó Z, Bereczky Z, Katona E, Adany R, Muszbek L. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost. 2007;97(3):458-463.
28. Koshland DE. Application of a theory of enzyme specificity to protein synthesis. Proc Natl Acad Sci U S A. 1958;44(2):98-104.
29. Geersing GJ, Janssen KJ, Oudega R, et al. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. Br Med J. 2009;339:b2990.
30. Karami-Djurabi R, Klok FA, Kooiman J, Velthuis SI, Nijkeuter M, Huisman MV. D-dimer testing in patients with suspected pulmonary embolism and impaired renal function. Am J Med. 2009;122(11):1050-1053.
31. Lobo JL, Zorrilla V, Aizpuru F, et al. D-dimer levels and 15-day outcome in acute pulmonary embolism. Findings from the RIETE registry. J Thromb Haemost. 2009;7(11):1795-1801.
32. Koch HJ, Horn M, Bogdahn U, Ickenstein GW. The relationship between plasma D-dimer concentrations and acute ischemic stroke subtypes. J Stroke Cerebrovasc Dis. 2005;14(2):75-79. (Pubitemid 40332497)
33. Skoloudik D, Bar M, Sanak D, et al. D-dimers increase in acute ischemic stroke patients with the large artery occlusion, but do not depend on the time of artery recanalization. J Thromb Thrombolysis. 2010;29(4):477-482.